What's behind slow site activation?
Sean Stanton of Bioclinica Research provides meaningful insights on study site activation in his latest article, 'Improving Site Activation: Three-Fold Solution' published in ICT's August 2017 issue.
Having spent the last 25 years of his career focused on creating successful, high-performing research sites, Sean gives a candid look at site activation — a rarely explored activity critical to laying the foundation for a successful study. To date, he's led the start-up of 25 trial sites, six inpatient hospitals and 19 outpatient clinics where more than 5,000 trials have been conducted leading to over 50 drug approvals.
From these experiences he shares, "Astonishingly, the same four problems that delayed trial start-ups 20 years ago are still doing so today; very little has changed." In the article Sean explores common trouble spots experienced by sponsors, CROs and investigator sites who consistently name redundant training and certiﬁcation, budgeting and contracting issues, vendor relations and scheduling concerns as the top reasons why site activation can take up to a year. Certainly, these are not the only issues that cause stoppage. Feasibility studies, regulatory matters and institutional review board (IRB) approvals play their part.
With some adjustments in the site activation approach, stakeholders can turn this around. Sean looks at the root causes of delays and goes on to outline a three-fold solution to speed up trial start dates — potentially reducing site activation times to as little as 30 days.
Get meaningful insights into site activation from Sean's unique perspective. Access the full article here and get practical first-hand advice and a solution that you can put into immediate action.
To consult with Sean or another Bioclinica expert, submit an online inquiry and we'll be in touch. And drop us a line anytime! We'd love to hear from you about what is, or is not, working for you in your clinical trials.